Results 141 to 150 of about 11,668 (257)

Cyclic infusion mitigates liver dysfunction associated with continuous total parenteral nutrition in a novel murine model. [PDF]

Am J Physiol Gastrointest Liver Physiol
Willis NB, Mims TS, Antunes K, Peng H, Yen MI, Yen CE, Pierre JF.   +6 more
europepmc   +1 more source

Quantitative prediction of intravenous drug interactions caused by cytochromes P450 inhibitors and inducers

British Journal of Clinical Pharmacology, Volume 92, Issue 8, Page 2682-2692, August 2026.
Background Aims Pharmacokinetic interaction studies typically focus on oral administration, but intravenous (IV) administration bypasses intestinal degradation and hepatic first‐pass metabolism, leading to distinct drug–drug interaction (DDI) magnitude. This study aimed to develop a predictive model for DDIs involving IV‐administered drugs.
Vianney Tuloup, Michel Tod, Laurent Bourguignon   +2 more
wiley   +1 more source

Treatment-Resistant Hypophosphataemia After Ferric Carboxymaltose: Expanding the Spectrum of 6h Syndrome (Hypophosphataemia, Hyperphosphaturia, Hypovitaminosis D, Hypocalcaemia, Secondary Hyperparathyroidism, High Fibroblast Growth Factor-23). [PDF]

Eur J Case Rep Intern Med
Rashid L.
europepmc   +1 more source

Contraindicated drug–drug interactions and associated adverse drug reactions in an observational cohort study of 4543 paediatric hospitalized patients

British Journal of Clinical Pharmacology, Volume 92, Issue 8, Page 2834-2852, August 2026.
Abstract Background and Purpose Drug–drug interactions (DDIs) are associated with an increased risk of adverse drug reactions (ADRs). Hospitalized children are particularly vulnerable to DDIs and ADRs due to polypharmacy, frequent use of unlicensed or off‐label medications, and dosing regimens often extrapolated from adult data.
Emilie Laval, Sylvain Goutelle, Inesse Boussaha, Xavier Dode, Yanis Mimouni, Kim An Nguyen, Behrouz Kassai   +6 more
wiley   +1 more source

Transition from Parenteral to Subcutaneous Application of Systemic Oncological Therapy for Treating Non-Small-Cell Lung Cancer. [PDF]

Curr Oncol
Muratovic A, Janzic U.
europepmc   +1 more source

Neonatal Bloodstream Infections: A Narrative Review on Diagnostic and Therapeutic Challenges and Prospects in Developing Countries

Health Science Reports, Volume 9, Issue 8, August 2026.
ABSTRACT Background Bloodstream infections (BSIs) pose a significant global health challenge, particularly in developing countries. Neonates are highly vulnerable due to underdeveloped immune systems and immature physical barriers, a risk amplified by poor hygiene and limited healthcare access in low‐ and middle‐income countries (LMICs), leading to an ...
Alex Odoom, Abdul‐Halim Osman, Onyansaniba K. Ntim, Fleischer C. N. Kotey, Eric S. Donkor   +4 more
wiley   +1 more source

Playing CATCH-up: a case report of profound protein-losing enteropathy and gastrointestinal haemorrhage from intestinal lymphangiectasia in DiGeorge syndrome. [PDF]

Eur Heart J Case Rep
Carrigan L, Yap J, Cheung M.
europepmc   +1 more source

Myocardial Lipid Metabolism Imbalance: The Pathological Core and Novel Diagnostic‐Therapeutic Directions of Cardiovascular Diseases

Journal of Biochemical and Molecular Toxicology, Volume 40, Issue 8, August 2026.
In cardiac cells, Plin5/AMPK regulate lipid homeostasis; excess CD36‐mediated uptake drives lipotoxicity, mitochondrial dysfunction, and CVDs (e.g., heart failure). Biomarkers (ApoB/ApoA‐1) and therapies (SGLT2 inhibitors) target this cascade. ABSTRACT Cardiac lipid metabolism is fundamental to myocardial energy homeostasis, with fatty acid oxidation ...
Peiyun Xie, Qun Zeng, Hongrui Wang, Meihua She   +3 more
wiley   +1 more source

Risk of Treatment Failure in Outpatient Parenteral Antimicrobial Therapy From an Academic Medical Center in Kentucky. [PDF]

Open Forum Infect Dis
Worsham Behal K, Stoner BJ, Schadler A, Burgess D, Burgess DS, Mynatt RP.   +5 more
europepmc   +1 more source

An Open‐Label, 2‐Period, Fixed Sequence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Doses of STS101 (Dihydroergotamine Nasal Powder), with and without Concomitant Itraconazole in Healthy Adult Subjects

The Journal of Clinical Pharmacology, Volume 66, Issue 8, August 2026.
Abstract Dihydroergotamine (DHE) prescribing information contains a boxed warning regarding the possibility of serious and/or life‐threatening peripheral ischemia with co‐administration of strong cytochrome P450 3A4 (CYP3A4) inhibitors. The effects of the strong CYP3A4 inhibitor itraconazole on the pharmacokinetics and safety of nasally administered ...
Detlef Albrecht, Elizabeth Hussey, Richard B. Lipton   +2 more
wiley   +1 more source